Collectively, these results suggest the likely clinical potential of TEAD4-specific therapeutic inhibitors within the context of mesothelioma, whose potency may be enhanced relative to less effective TEAD1-specific inhibitors and whose specificity may be beneficial to avoid the kidney toxicity associated with pan-TEAD inhibition (61). This evidence concerns the gene TEAD1 and mesothelioma.